Search
Close this search box.

Client Success: Derivatives Valuation for pre-IPO Biotechnology Company

Client Success: Derivatives Valuation for pre-IPO Biotechnology Company

THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION: RNA worked with the company and their Big 4 auditor to develop a Monte Carlo […]

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.